ARTICLE | Company News
Aestus Therapeutics, Astellas deal
July 5, 2010 7:00 AM UTC
Astellas granted Aestus an exclusive, worldwide license to FK614. Aestus, which renamed the compound ATx08-001, plans to start a Phase II trial of the peroxisome proliferation activated receptor (P...